Research Topics
| Christopher M BoothSummaryAffiliation: Queen's University Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based studyChristopher M Booth
Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Canada
Cancer 119:1243-50. 2013..This is the first report describing the association between time to adjuvant chemotherapy (TTAC) and survival in non-small cell lung cancer (NSCLC)...- Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, CanadaChristopher M Booth
Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Canada
J Thorac Oncol 7:559-66. 2012..Herein, we describe chemotherapy regimens used, dose modifications, survival, and treatment-related toxicity in the general population... - Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretationChristopher M Booth
NCIC Clinical Trials Group and Queen s University Cancer Research Institute, Kingston, Canada
Eur J Cancer 47:854-63. 2011..To assess methodology, results and interpretation of oncology randomised controlled trials closed early for benefit (RCTCEB)... - Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the pastChristopher M Booth
Queen s University Cancer Research Institute, Kingston, Canada
Clin Cancer Res 16:5963-71. 2010.... - The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, CanadaChristopher M Booth
Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Ontario, Canada
Cancer 116:4160-7. 2010..Lower socioeconomic status (SES) is associated with worsened cancer survival. The authors evaluate the impact of SES on stage of cancer at diagnosis and survival in Ontario, Canada... 
Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes studyChristopher M Booth
Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, 10 Stuart St, Kingston, Ontario K7L 3N6, Canada
J Clin Oncol 28:3472-8. 2010..Here, we evaluate the uptake of ACT and its impact on outcomes in the general population of Ontario, Canada...- Presentation of nonfinal results of randomized controlled trials at major oncology meetingsChristopher M Booth
National Cancer Institute of Canada Clinical Trials Group, Cancer Research Institute, Queen s University, Kingston, ON, Canada
J Clin Oncol 27:3938-44. 2009..To assess the frequency, implications, and factors associated with reporting nonfinal analyses (NFAs) of randomized controlled trials (RCTs) as abstract publications... 
Translating new medical therapies into societal benefit: the role of population-based outcome studiesChristopher M Booth
Division of Cancer Care and Epidemiology, Queen's University, Kingston, Ontario, Canada
JAMA 300:2177-9. 2008- Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)Christopher M Booth
National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada
Eur J Cancer 44:19-24. 2008..This report summarises the scientific reviews and discussions as well as the recommendations regarding phase I trial design formulated by the MDICT task force... - Evolution of the randomized controlled trial in oncology over three decadesChristopher M Booth
National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
J Clin Oncol 26:5458-64. 2008..The randomized controlled trial (RCT) is the gold standard for establishing new therapies in clinical oncology. Here we document changes with time in design, sponsorship, and outcomes of oncology RCTs... - Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysisJames J Biagi
Department of Oncology, Queen s University, Kingston, Ontario, Canada
JAMA 305:2335-42. 2011..Adjuvant chemotherapy (AC) improves survival among patients with resected colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown... - External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancerChristopher M Booth
National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Canada
BMC Cancer 7:110. 2007..In this paper we review external factors that may influence decision-making bodies and present a case study of media response in Ontario, Canada to adjuvant trastuzumab for breast cancer... - Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?Christopher M Booth
National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
J Clin Oncol 26:6-8. 2008 - Adjuvant chemotherapy for resected non-small cell lung cancerChristopher M Booth
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
J Thorac Oncol 1:180-7. 2006..In this review, we describe early adjuvant trials and highlight the recent landmark studies in this disease. The focus of ongoing and future research efforts is also discussed... - Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?Pavlo Ohorodnyk
NCIC Clinical Trials Group, Queen s University, Kingston, ON, Canada
Eur J Cancer 45:2249-52. 2009..In the trial by Burris et al. CB was a composite measure of pain, performance status and weight. Here we describe how CB has been used in oncology trials since that time... - Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancerAbdullah K Altwairgi
Cancer Center of Southeastern Ontario, Queen s University, 25 King St West, Kingston, Ontario, Canada
J Clin Oncol 30:3552-7. 2012..However, discordances have been noticed in summary conclusions in the abstracts and the main body of some articles. This article evaluated such discordances in detail... - Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)Christopher M Booth
National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, ON, Canada
Eur J Cancer 44:25-9. 2008..The MDICT cautioned on the use of small randomised trials which have a number of statistical pitfalls and dangers and strongly encouraged the complete reporting, including negative trials, in the scientific literature... - Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?Camilla Zimmermann
Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, Toronto, ON, Canada, M5G 2M9
J Pain Palliat Care Pharmacother 19:25-31. 2005..A possible conversion method for rotation to methadone for patients with escalating pain and opioid use is suggested...